S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged

MYT Netherlands Parent B.V. (MYTE) Stock Forecast & Price Target

$3.83
-0.02 (-0.52%)
(As of 04/19/2024 08:51 PM ET)

MYT Netherlands Parent B.V. Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$5.31
38.71% Upside
High Forecast$8.00
Average Forecast$5.31
Low Forecast$4.00
TypeCurrent Forecast
4/23/23 to 4/22/24
1 Month Ago
3/24/23 to 3/23/24
3 Months Ago
1/23/23 to 1/23/24
1 Year Ago
4/23/22 to 4/23/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.31$5.88$6.07$10.75
Predicted Upside38.71% Upside25.56% Upside22.16% Upside24.49% Upside
Get MYT Netherlands Parent B.V. Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MYTE and its competitors with MarketBeat's FREE daily newsletter.

MYTE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MYTE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MYT Netherlands Parent B.V. Stock vs. The Competition

TypeMYT Netherlands Parent B.V.Retail/Wholesale CompaniesS&P 500
Consensus Rating Score
2.33
2.42
2.49
Consensus RatingHoldHoldHold
Predicted Upside38.71% Upside54.01% Upside11.97% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/16/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$5.00 ➝ $4.75+58.33%
9/18/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual Weight ➝ Equal Weight$6.00 ➝ $4.50+8.70%
6/29/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$14.00 ➝ $8.00+124.09%
6/26/2023500.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
6/14/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$19.00 ➝ $4.00-0.99%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:20 AM ET.

MYTE Price Target - Frequently Asked Questions

What is MYT Netherlands Parent B.V.'s consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for MYT Netherlands Parent B.V. stock is Hold based on the current 2 hold ratings and 1 buy rating for MYTE. The average twelve-month price prediction for MYT Netherlands Parent B.V. is $5.31 with a high price target of $8.00 and a low price target of $4.00. Learn more on MYTE's analyst rating history.

Do Wall Street analysts like MYT Netherlands Parent B.V. more than its competitors?

Analysts like MYT Netherlands Parent B.V. less than other Retail/Wholesale companies. The consensus rating score for MYT Netherlands Parent B.V. is 2.33 while the average consensus rating score for retail/wholesale companies is 2.41. Learn more on how MYTE compares to other companies.

Does MYT Netherlands Parent B.V.'s stock price have much upside?

According to analysts, MYT Netherlands Parent B.V.'s stock has a predicted upside of 43.41% based on their 12-month stock forecasts.

What analysts cover MYT Netherlands Parent B.V.?

MYT Netherlands Parent B.V. has been rated by UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:MYTE) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners